Marjolijn Ligtenberg Networking around aberrant genes
In the treatment of patients with cancer, hereditary predisposition and tumor-specific genetic characteristics play an increasingly important role.read more
Marjolijn Ligtenberg Networking around aberrant genesIn the treatment of patients with cancer, hereditary predisposition and tumor-specific genetic characteristics play an increasingly important role. Recognizing a genetic predisposition for developing cancer helps to prevent cancer or to detect it at an early stage. In addition, genetic predisposition and tumor-specific genetic features can guide the choice of therapy, for example for the application of new cancer medicines. This requires good coordination between different disciplines. Professor Marjolijn Ligtenberg and her team have made a significant contribution to the identification of tumor-genetic features and their clinical application. Rapidly advancing technological developments in detecting these characteristics are accompanied by accumulating knowledge about the use of this information for the benefit of the patient. Therefore, multidisciplinary collaboration, optimization and evaluation of diagnostic procedures remain of utmost importance to help patients effectively.
Date, time and location Inaugural lecture
- Date: 23 March 2018
- Time: 15:45 hrs
- Location: Radboud Universiteit, Academiezaal Aula, Comeniuslaan 2
Marjolijn Ligtenberg (1962) studied Biology at Utrecht University. From 1986 to 1993 she worked at the Netherlands Cancer Institute. In 1991 she obtained her PhD on research on the genetic background and function of a tumor marker at the University of Amsterdam. In 1993 she came to Radboudumc as a postdoctoral researcher at the department of Human Genetics. Shortly thereafter she expanded her activities to the Pathology department and her research focused on the identification and application of tumor-genetic markers for personalized cancer care. Ligtenberg is head of the interdepartmental Laboratory of Tumor Genetics of the Radboudumc, where the diagnostics of hereditary cancer and tumor-specific genetic characteristics is integrated